Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside
Oppenheimer initiated coverage on Vaxart Inc. VXRT, an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines.
Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript
Vaxart, Inc. (NASDAQ:VXRT ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Ed Berg - SVP & General Counsel Steven Lo - CEO Sean Tucker - Founder & Chief Scientific Officer James Cummings - Chief Medical Officer Phil Lee - CFO Conference Call Participants Elaine Kim - Cantor Fitzgerald Operator Greetings and welcome to the Vaxart Business Update and Second Quarter 2024 financial results, conference call, a question and answer session will follow management's opening remarks. Individual investors may submit written questions to IR at vaxart.com As a reminder, this conference is being recorded.
VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates
VAXART, INC. (VXRT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of $0.03.
Vaxart Inc: Asymmetric Risk-Reward Opportunity Following BARDA Funding
Vaxart Inc is developing oral vaccines for COVID-19, norovirus, and influenza with promising early clinical results but financial struggles. Vaxart received $453M funding from BARDA for a 10,000-patient Phase 2b trial comparing their COVID-19 oral vaccine to an mRNA vaccine. Despite a stock price spike following the news, Vaxart faced investor disappointment with a $40M offering shortly after the BARDA funding announcement.
